In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Philips Healthcare: Building Bridges From The Hospital To The Home

Executive Summary

Changing health care models is difficult, but most stakeholders know what modern and sustainable health care delivery should look like. Philips Healthcare has restructured its operations and aims to take a lead role in maximizing home-based health care, tailored to the patient.

You may also be interested in...



Philips Targets Bolt-On Deals That Meet Demand At The Point Of Care

Philips, a giant of the medical systems and software industry, maintains its strategic direction with organic and external growth. That was illustrated in one recent four-month period in which the group made seven acquisitions, adding to its non-invasive diagnostics portfolio Electrical Geodesics and bolstering its steps in therapeutic medical devices with the acquisition of Spectranetics. But whatever the target, the same ground rules apply.

ChatGPT Unleashed: Generative AI Use Cases Taking Off In Pharma

As generative AI and its star avatar, ChatGPT, take the world by storm, pharma is seeing traction for use cases around smarter pharmacovigilance and commercial marketing content development, among others. Senior executives from Indegene discuss this and more in an interview with Scrip.

Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage

Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. Brian Yang takes a deeper look into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel